drugset / Trial / NCT04897386
Monitoring the Efficacy of Duvalizumab Combined With Neoadjuvant Chemotherapy for Ib-IIIb NSCLC by Sequencing of Immune Receptor Repertoire: a Prospective, One Arm Clinical Study
Phase 2
Unknown
30 enrolled
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
NaSingle-groupOpen-labelTreatment
Summary
To observe and evaluate the efficacy and safety of Duvalizumab Combined With Neoadjuvant Chemotherapy for Ib-IIIb NSCLC and the relevance with Immune Receptor Repertoire
Timeline
- Start
- 2021-06-01
- Primary completion
- 2024-06-01
- Completion
- 2024-12-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Duvalizumab | Unknown | 1500 mg | — |
| Background | Pemetrexed | Small molecule | 850 mg | Intravenous |